Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps

Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9

Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during

Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercep

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the ana

LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Compan

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early huma

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans,

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company adva

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks C

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the ana

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and

Keros Therapeutics  KROS reshaped its financial profile in 2025 by pairing a major licensing transac

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward

Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage

Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight

Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the ana

B of A Securities analyst Jason Zemansky maintains Keros Therapeutics (NASDAQ:KROS) with a Neutra

Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are al

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. S

Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company p

U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. H

  On Wednesday, 311 stocks hit new 52-week lows.

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares jumped 144.5% to $0.7827.

Upgrades

  On Thursday, 216 stocks hit new 52-week lows.

  On Tuesday, 951 companies hit new 52-week lows.